Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNKP | Q96T60 | 7/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000245 | 0.81 | PNKP (1.00) | PNKPUSP2HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL22000597 | 0.81 | PNKP (1.00) | PNKPUSP2HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL22000411 | 0.81 | PNKP (1.00) | PNKPUSP2HSD17B10HCRTR1HCRTR2 | |
| SCHEMBL4542015 | 0.64 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4369528 | 0.63 | GAA (0.54) | PNKPHCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL4534136 | 0.63 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL25798826 | 0.62 | CETP (0.59) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL2350546 | 0.62 | L3MBTL1 (0.56) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL21015413 | 0.62 | IDO1 (0.47) | GAAALDH1A1MAPTCYP2D6L3MBTL1 | |
| SCHEMBL4536117 | 0.62 | HCRTR1 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325905-B2 | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-05-10 | — | — | US | disclosed |
| US-20200148675-A1 | IMIDOPIPERIDINE COMPOUNDS AS INHIBITORS OF HUMAN POLYNUCLEOTIDE KINASE PHOSPHATASE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325905-B2 | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | PNKP, PPM1A, PPM1B | PNKP 1/4885USP2 1847/4885HSD17B10 3619/4885 |
| US-20200148675-A1 | IMIDOPIPERIDINE COMPOUNDS AS INHIBITORS OF HUMAN POLYNUCLEOTIDE KINASE PHOSPHATASE | PNKP, PPM1A, PPM1B | PNKP 1/4885USP2 1847/4885HSD17B10 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.